BPI 2026 has ended. This guide stays up as the record of who was there. Next: BPI 2027, Sep 20–23, 2027 in Boston

Johnson & Johnson at BPI 2026

Sep 22–25, 2026 Boston, MA ~3k attendees Website

Johnson & Johnson takes part in 3 sessions at BPI 2026 in Boston. Its program concerns antibody product quality and cell line strategy. Sessions examine galactosylation of the antibody Fc region and host cell protein challenges in antibody manufacturing, and ask whether cell lines for multispecifics and gene therapy are still built with monoclonal antibody thinking.

OrganizationBPI 2026 Attendance
Johnson & Johnson
New Brunswick, New Jersey
Large pharma
Global healthcare company whose Innovative Medicine segment develops, manufactures and markets pharmaceuticals including antibodies and cell therapies.
Talk
Wed Sep 23
9:00am–9:30am
Study on Galactosylation Modification of Monoclonal Antibodies Fc Region
Cell Line Development & Engineering
Talk
Thu Sep 24
2:15pm–2:45pm
Talk
Fri Sep 25
9:00am–10:00am
Fireside Chat: New Modalities, Old Playbook: Are Multispecifics and Gene Therapy Cell Lines Stuck in mAb Thinking?
Cell Line Development & Engineering · with Pfizer, Bristol Myers Squibb, Prolific Machines

Explore the full BPI 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full BPI 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Johnson & Johnson

Tell us what you sell and we’ll find the people at Johnson & Johnson most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the BioProcess International Conference & Exhibition or its organizers. Submit a correction